Hungarian contract research organisation (CRO) Citoxlab Group has signed an agreement to acquire another Hungary-based CRO named Solvo Biotechnology.

The target company has sites in Budapest and Szeged and a workforce of 100. It specialises in drug transporter studies and assessment of drug-drug interactions (DDI).

The acquisition will strengthen Citoxlab’s business in the non-clinical CRO field.

Medical Prognosis Institute (MPI) A/S and Oncology Venture Sweden AB (OV) have signed an agreement on a joint merger plan.

The merger of the two companies will result in the establishment of an integrated oncology biotechnology company named Oncology Venture.

The shareholders of OV will get 1.8524 shares of MPI for each share in OV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MPI is a biotechnology company, while OV is a biopharmaceutical company focused on oncology.

“The company initially paid 4.8 million shares to the shareholders of IB, while the remaining 6.2 million will be issued before September 2018.”

Both companies involved in the merger are based in Denmark.

Contract development and manufacturing organisation Ardena Holding NV (Ardena) has acquired ChemConnection BV.

Both companies involved in the transaction are based in the Netherlands.

The acquisition will enable the acquirer company to set-up an integrated drug development company.

Flying Brands Limited has acquired 100% stake in Imaging Biometrics LLC (IB).

Flying Brands paid $68,000 in cash and 11 million ordinary shares of the company at €0.04 ($0.04) a share. The company initially paid 4.8 million shares to the shareholders of IB, while the remaining 6.2 million will be issued before September 2018.

Based in the UK, the acquirer company is a medical services and software company, while the target company is a US-based developer of software applications for the healthcare industry.

Flying Brands appointed Peterhouse Corporate Finance Limited as the financial advisor for the transaction.